Related references
Note: Only part of the references are listed.Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells
Genevieve L. Weber et al.
Oncotarget (2015)
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Lauren M. Thorpe et al.
NATURE REVIEWS CANCER (2015)
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
Claudia Fumarola et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Molecular Determinants of Outcome With Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Helen J. Mackay et al.
CANCER (2014)
Naturally Occurring Neomorphic PIK3R1 Mutations Activate the MAPK Pathway, Dictating Therapeutic Response to MAPK Pathway Inhibitors
Lydia W. T. Cheung et al.
CANCER CELL (2014)
Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity
Oliver Ou et al.
CANCER LETTERS (2014)
Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
Katherine A. Hoadley et al.
CELL (2014)
Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2-Targeted Therapies for Breast Cancer
Daniel J. Zabransky et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Jiri Polivka et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
Filip Janku et al.
CELL REPORTS (2014)
Challenges in the clinical development of PI3K inhibitors
Cristian Massacesi et al.
INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE (2013)
PIK3R1 underexpression is an independent prognostic marker in breast cancer
Magdalena Cizkova et al.
BMC CANCER (2013)
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2013)
The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
Jing Li et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Pan-cancer patterns of somatic copy number alteration
Travis I. Zack et al.
NATURE GENETICS (2013)
The Cancer Genome Atlas Pan-Cancer analysis project
John N. Weinstein et al.
NATURE GENETICS (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
Ines M. Macias-Perez et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Targeting PI3K in cancer: any good news?
Miriam Martini et al.
FRONTIERS IN ONCOLOGY (2013)
Targeting mTOR Pathways in Human Malignancies
Angelica Fasolo et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
An emerging toolkit for targeted cancer therapies
Gordon B. Mills
GENOME RESEARCH (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Recurrent R-spondin fusions in colon cancer
Somasekar Seshagiri et al.
NATURE (2012)
Targeted therapies: how personal should we go?
Miriam Martini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Somatic Mutations of PIK3R1 Promote Gliomagenesis
Steven N. Quayle et al.
PLOS ONE (2012)
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Jing Ni et al.
CANCER DISCOVERY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer
Euan A. Stronach et al.
CANCER RESEARCH (2011)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer
Vienna Ludovini et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Structure of Lipid Kinase p110β/p85β Elucidates an Unusual SH2-Domain-Mediated Inhibitory Mechanism
Xuxiao Zhang et al.
MOLECULAR CELL (2011)
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Lydia W. T. Cheung et al.
CANCER DISCOVERY (2011)
Nuclear β-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells
Masahiro Uchino et al.
BMC CANCER (2010)
Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
Kyle A. Edgar et al.
CANCER RESEARCH (2010)
The Phosphoinositide 3-Kinase Regulatory Subunit p85α Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling
Cullen M. Taniguchi et al.
CANCER RESEARCH (2010)
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
J. A. DiMasi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Subtle variations in Pten dose determine cancer susceptibility
Andrea Alimonti et al.
NATURE GENETICS (2010)
Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110α
Minghao Sun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase
Ryaz B. Chagpar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Nathan T. Ihle et al.
CANCER RESEARCH (2009)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines
Kathryn Balmanno et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
p85 Associates with Unphosphorylated PTEN and the PTEN-Associated Complex
Rosalia Rabinovsky et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110 alpha and are disrupted in oncogenic p85 mutants
Haiyan Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt
X. Yang et al.
BRITISH JOURNAL OF CANCER (2008)
Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells
Rosaline C-Y. Hui et al.
MOLECULAR CANCER THERAPEUTICS (2008)
PI3K pathway alterations in cancer: variations on a theme
T. L. Yuan et al.
ONCOGENE (2008)
The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ
Julie Guillermet-Guibert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations
Chuan-Hsiang Huang et al.
SCIENCE (2007)
Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit
Nabil Miled et al.
SCIENCE (2007)
Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers
Barbara Geering et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Trastuzumab: triumphs and tribulations
R. Nahta et al.
ONCOGENE (2007)
PRAS40 deregulates apoptosis in malignant melanoma
SubbaRao V. Madhunapantula et al.
CANCER RESEARCH (2007)
Rare cancer-specific mutations in PIK3CA show gain of function
Marco Gymnopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
Yan Lu et al.
PLOS MEDICINE (2006)
A PI3K activity-independent function of p85 regulatory subunit in control of mammalian cytokinesis
Zaira Garcia et al.
EMBO JOURNAL (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex
J Luo et al.
JOURNAL OF CELL BIOLOGY (2005)
Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility
SP Barwe et al.
MOLECULAR BIOLOGY OF THE CELL (2005)
Gene-targeting reveals physiological roles and complex regulation of the phosphoinositide 3-kinases
LC Foukas et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2003)
Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival
K Ueki et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Phosphoinositide 3-kinase in immunological systems
DA Fruman et al.
SEMINARS IN IMMUNOLOGY (2002)
Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-κB
C Murga et al.
ONCOGENE (2002)
Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase
BD Cuevas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Phosphoinositide-3 kinase binds to a proline-rich motif in the Na+,K+-ATPase α subunit and regulates its trafficking
GA Yudowski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
